Comparison of absorption rates in bioequivalence studies of immediate release drug formulations
- PMID: 1592542
Comparison of absorption rates in bioequivalence studies of immediate release drug formulations
Abstract
For immediate release drug formulations, the maximum concentration (Cmax), the time to the maximum concentration (tmax), the mean residence time (MRT), and recently, the Cmax/AUC ratio have been suggested as absorption rate characteristics. Several authors have used simulation studies to investigate the relative merits of these characteristics. In contrast, we investigate here the "true" relationships between these four characteristics in a more theoretical manner. Specifically, we show that in the one-compartment open model the difference in tmax, and the ratio of the Cmax/AUC ratio of two drug formulations are equivalent characteristics for the comparison of the absorption rate of two drug formulations. In two- or higher compartment models these relationships hold approximately. This provides a powerful argument for the use of the observed Cmax/AUC ratio, rather than tmax, as a measure for the rate of absorption, because it is well-known that Cmax/AUC can be observed with higher precision than tmax. We also show that the difference in MRT for two-drug formulations equals the difference in mean absorption time under very general conditions, and for the one- and the two-compartmental model we prove this explicitly. Thus the difference in MRT emerges as the most direct characteristic of the difference in absorption rates, and in that sense is superior to both the tmax difference and the Cmax/AUC ratio. Based on empirical evidence and the results of simulation studies published in the literature we recommend that for drugs with short elimination half-lives, the difference in MRT is the primary characteristic for the comparison of absorption rates.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.Int J Clin Pharmacol Ther. 1994 Jul;32(7):323-8. Int J Clin Pharmacol Ther. 1994. PMID: 7952792
-
In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.Biopharm Drug Dispos. 2004 Mar;25(2):91-8. doi: 10.1002/bdd.390. Biopharm Drug Dispos. 2004. PMID: 14872557 Clinical Trial.
-
Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies.Int J Clin Pharmacol Ther. 1994 Dec;32(12):633-7. Int J Clin Pharmacol Ther. 1994. PMID: 7881699
-
Pharmacokinetic characterization of controlled-release formulations.Eur J Drug Metab Pharmacokinet. 1990 Apr-Jun;15(2):173-81. doi: 10.1007/BF03190201. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2200687 Review.
-
Metrics for the evaluation of bioequivalence of modified-release formulations.AAPS J. 2012 Dec;14(4):813-9. doi: 10.1208/s12248-012-9396-8. Epub 2012 Aug 22. AAPS J. 2012. PMID: 22910857 Free PMC article. Review.
Cited by
-
Cubic spline functions and polynomials for calculation of absorption rate.Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):469-73. doi: 10.1007/BF03189997. Eur J Drug Metab Pharmacokinet. 1998. PMID: 10323329
-
Pharmacokinetic Parameters Determination and In Vitro-In Vivo Correlation of Ileocolonic-Targeted pH-Responsive Coated Mini-Tablets of Naproxen.Sci Pharm. 2015 Jun 2;83(4):645-58. doi: 10.3797/scipharm.1503-16. Print 2015 Oct-Dec. Sci Pharm. 2015. PMID: 26839845 Free PMC article.
-
Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers.Clin Pharmacokinet. 2006;45(3):317-24. doi: 10.2165/00003088-200645030-00007. Clin Pharmacokinet. 2006. PMID: 16509763 Clinical Trial.
-
Novel direct curve comparison metrics for bioequivalence.Pharm Res. 2001 Jun;18(6):734-41. doi: 10.1023/a:1011067908500. Pharm Res. 2001. PMID: 11474775
-
Absorption rate vs. exposure: which is more useful for bioequivalence testing?Pharm Res. 1996 Mar;13(3):453-6. doi: 10.1023/a:1016061013606. Pharm Res. 1996. PMID: 8692741